Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barr syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Annexon, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BRISBANE, CALIF., AUG. 18, 2025 (GLOBE NEWSWIRE) -- ANNEXON, INC. (NASDAQ: ANNX),A BIOPHARMACEUTICAL COMPANY ADVANCING A LATE-STAGE CLINICAL PLATFORM OF NOVEL THERAPIES FOR PEOPLE LIVING WITH DEVASTATING CLASSICAL COMPLEMENT-MEDIATED NEUROINFLAMMATORY DISEASES OF THE BODY, BRAIN, AND EYE, TODAY ANNOUNCED THAT IT HAS GRANTED INDUCEMENT TO A NEW NON-EXECUTIVE EMPLOYEE UNDER THE TERMS OF THE 2022 EMPLOYMENT INDUCEMENT AWARD PLAN. THE EQUITY AWARD WAS APPROVED ON AUGUST 11, 2025, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ANNEXON REPORTS INDUCEMENT GRANT TO NEW EMPLOYEE UNDER NASDAQ LISTING RULE 5635(C)(4)

TANRUPRUBART (FORMERLY ANX005) FOR GBS ADVANCING THROUGH REGULATORY INTERACTIONS; MAA SUBMISSION IN EUROPE ANTICIPATED IN FIRST QUARTER OF 2026; ONGOING DISCUSSIONS WITH FDA REGARDING GENERALIZABILITY PACKAGE TO SUPPORT A BLA ACCELERATED COMPLETION OF ENROLLMENT FOR GLOBAL PHASE 3 ARCHER II TRIAL OF VONAPRUMENT (FORMERLY ANX007) FOR DRY AMD WITH GA; SELECTED FOR EMA PRIME PRODUCT DEVELOPMENT CANDIDATE PILOT; TOPLINE ARCHER II DATA EXPECTED IN SECOND HALF OF 2026 ANX1502 FIRST-IN-KIND ORAL C1S INHIBITOR EXPOSURE EXCEEDED TARGET CONCENTRATION IN FASTED PATIENTS; EVALUATION IN RELATION TO FOOD INTAKE ONGOING IN PROOF-OF-CONCEPT CAD STUDY, UPDATE EXPECTED BY YEAR-END 2025 $227 MILLION IN CASH SUPPORTS OPERATIONS INTO THE FOURTH QUARTER OF 2026 THROUGH VONAPRUMENT TOPLINE PHASE 3 DATA IN GA BRISBANE, CALIF., AUG. 14, 2025 (GLOBE NEWSWIRE) -- ANNEXON, INC. (NASDAQ: ANNX), A BIOPHARMACEUTICAL COMPANY ADVANCING A LATE-STAGE CLINICAL PLATFORM OF NOVEL THERAPIES FOR PEOPLE LIVING WITH DEVASTATING CLASSICAL COMPLEMENT-MEDIATED NEUROINFLAMMATORY DISEASES OF THE BODY, BRAIN, AND EYE, TODAY HIGHLIGHTED PORTFOLIO PROGRESS, ANNOUNCED KEY ANTICIPATED MILESTONES AND REPORTED SECOND QUARTER 2025 FINANCIAL RESULTS.

ANNEXON REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS, PORTFOLIO PROGRESS AND KEY ANTICIPATED MILESTONES

NEW PILOT APPOINTS DESIGNATED PRODUCT DEVELOPMENT COORDINATOR TO NAVIGATE REGULATORY INTERACTIONS, RESPOND TO AD-HOC QUERIES, AND SUPPORT EVIDENCE PLANNING

ANNEXON SELECTED BY EMA TO PARTICIPATE IN PRODUCT DEVELOPMENT COORDINATOR PILOT FOR VONAPRUMENT (ANX007) FOR DRY AGE-RELATED MACULAR DEGENERATION WITH GEOGRAPHIC ATROPHY

EXPEDITED ENROLLMENT SURPASSING 630 TARGETED PARTICIPANTS UNDERSCORES THE STRONG DEMAND FOR A THERAPY FOCUSED ON VISION PRESERVATION

ANNEXON ANNOUNCES COMPLETION OF ENROLLMENT IN PIVOTAL PHASE 3 ARCHER II TRIAL OF VONAPRUMENT (FORMERLY ANX007) FOR DRY AGE-RELATED MACULAR DEGENERATION (AMD) WITH GEOGRAPHIC ATROPHY

DR. CLARK BRINGS 25 YEARS OF EXPERIENCE TREATING RETINA DISEASES AND DEVELOPING EMERGING THERAPIES AS A PRINCIPAL INVESTIGATOR IN OVER 70 CLINICAL TRIALS AND AS AN EARLY PIONEER OF VEGF INHIBITORS

ANNEXON BOLSTERS OPHTHALMOLOGY EXPERTISE WITH APPOINTMENT OF RETINA SPECIALIST LLOYD CLARK, M.D., AS PIVOTAL ANX007 PROGRAM ADVANCES IN DRY AGE-RELATED MACULAR DEGENERATION (AMD) WITH GEOGRAPHIC ATROPHY (GA)

BRISBANE, CALIF., MAY 29, 2025 (GLOBE NEWSWIRE) -- ANNEXON, INC. (NASDAQ: ANNX), A BIOPHARMACEUTICAL COMPANY ADVANCING A LATE-STAGE CLINICAL PLATFORM OF NOVEL THERAPIES FOR PEOPLE LIVING WITH DEVASTATING CLASSICAL COMPLEMENT-MEDIATED NEUROINFLAMMATORY DISEASES OF THE BODY, BRAIN, AND EYE, TODAY ANNOUNCEDTHAT DOUGLAS LOVE, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, JUNE 4, 2025 AT 8:10 A.M. EST.

ANNEXON BIOSCIENCES TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

FIRST ORAL PRESENTATION OF THE TANRUPRUBART REAL-WORLD EVIDENCE (RWE) STUDY BY INTERNATIONAL GUILLAIN-BARR SYNDROME OUTCOMES STUDY (IGOS) RESEARCHERS HIGHLIGHTS BENEFITS OVER CURRENT STANDARD OF CARE IN MATCHED PATIENT POPULATIONS

ANNEXON SHOWCASES TANRUPRUBART DATA DEMONSTRATING IMPROVED CLINICAL OUTCOMES IN GUILLAIN-BARR SYNDROME (GBS) AT 2025 PERIPHERAL NERVE SOCIETY (PNS) ANNUAL MEETING

BRISBANE, CALIF., MAY 16, 2025 (GLOBE NEWSWIRE) -- ANNEXON, INC. (NASDAQ: ANNX), A BIOPHARMACEUTICAL COMPANY ADVANCING A LATE-STAGE CLINICAL PLATFORM OF NOVEL THERAPIES FOR PEOPLE LIVING WITH DEVASTATING CLASSICAL COMPLEMENT-MEDIATED NEUROINFLAMMATORY DISEASES OF THE BODY, BRAIN, AND EYE, TODAY ANNOUNCED THAT IT HAS GRANTED INDUCEMENT TO TWO NEW NON-EXECUTIVE EMPLOYEES UNDER THE TERMS OF THE 2022 EMPLOYMENT INDUCEMENT AWARD PLAN. THE EQUITY AWARDS WERE APPROVED ON MAY 14, 2025, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ANNEXON REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(C)(4)

FDA MEETING FOR TANRUPRUBART (FORMERLY ANX005), THE FIRST POTENTIAL TARGETED THERAPY FOR GBS, SCHEDULED FOR SECOND QUARTER 2025 AHEAD OF PLANNED BLA SUBMISSION

ANNEXON REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS, PORTFOLIO PROGRESS AND KEY ANTICIPATED MILESTONES

FIRST ORAL PRESENTATION BY THE INTERNATIONAL GUILLAIN-BARR SYNDROME OUTCOMES STUDY (IGOS) OF THE REAL-WORLD EVIDENCE (RWE) RESULTS SHOWING IMPROVED OUTCOMES WITH TANRUPRUBART (FORMERLY ANX005) COMPARED TO CURRENT STANDARDS OF CARE IN MATCHED PATIENT POPULATIONS

ANNEXON ANNOUNCES PRESENTATIONS ON THE CLINICAL ADVANCEMENT OF TANRUPRUBART AS THE FIRST POTENTIAL TARGETED THERAPY FOR GUILLAIN-BARR SYNDROME (GBS) AT THE 2025 PNS MEETING

Annexon, Inc.

ANNX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Annexon, Inc.

ANNX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ANNX